The aim of this study was to prepare a biocompatible and biodegradable nanoparticulate drug delivery system to increase the efficiency and bioavailability of oral drugs. Chitosan nanoparticles containing salicylic acid (SA) were prepared by emulsion method. The morphology of nanoparticles was characterized by scanning electron microscopy (SEM). Particle size distribution was examined by laser light scattering. The drug released and drug content was examined by UVspectroscopy. The effects of different initial drug loading on the drug content and drug released were investigated. The nanoparticles were spherical and the average size of them was 300 nm, the drug content was in the range of 20-35%. All the nanoparticles had a burst release initially and the burst release behavior of them conformed best to higuchi model. The release of SA from chitosan nanoparticles was Fickian.
Introduction
Nanoparticulate delivery systems have the potential to improve drug stability, increase the duration of the therapeutic effect and permit administration through nonparental routes. Oral delivery is the preferred route for administration because it is non-invasive, avoids injection, and decreases risk of infection. Oral administration is a more convenient approach considering the pain and possible infections caused by injections, thus leading to a higher patient compliance (Sarmento et al. [1] , Borges et al. [2] ). A successful oral drug delivery system needs to be developed on the basis of increased resistance of the drug carrier against gastrointestinal enzymes and pH gradients (i.e. from 1 to 3 in the stomach to 6 to7 in the intestine). In addition, timecontrolled release is also a pre-requisite for such oral drug delivery systems. Chitin and chitosan are linear polymers of (1-6)-linked-2-acetamido-2-deoxy-b-D-glucan (GlCNAC) and 2-amino-2-deoxy-b-D-glucan (GLCN) and finds numerous applications in agriculture, biomedicine (for example, as drug delivery system), paper-making, water treatment or food industry. The properties of chitosan strongly depend on the degree of acetylating (DA) (Taghizadeh et al. [3] ). Polymeric nanoparticles with biodegradable and biocompatible polymers are good candidates for particulate carriers to deliver drugs. Such particles are expected to be adsorbed in an intact form in the gastrointestinal tract after oral administration. Various preparation methods for polymeric nanoparticles, such as polymerization and emulsion solvent diffusion methods have been reported. Emulsion solvent diffusion (ESD) methods can be classified into two: the ""in water"" method and the ""in oil"" method (Sarmento et al. [4] ). Many drugs (protein, insulin, calcitonin, nucleic acid, vaccine, desmopressin, hemoglobin, cyclosporine a, etc.) have been extensively investigated using natural polymeric carriers (Borges et al. [2] Yamamoto et al. [5] , Takeuchi et al. [6] , Tahara et al. [7] , Sarmento et al. [8] , Polnok et al. [9] , Silva et al. [10] , Mei). Salicylic acid (SA) is a betahydroxy acid (BHA) with the formula C6H4 (OH) CO2H, which is used to treat warts, corns, acne, psoriasis, etc. (Gifani et al. [12] ). The short half-life, low bioavailability and severe gastric irritation make SA a suitable model for using in oral drug delivery systems.
In this research work the chitosan nanoparticles containing SA were successfully prepared by using the emulsion solvent diffusion "in oil" method which is easy way to obtain nanoparticles without freeze drying.
Results and discussion

Nanoparticles morphology and size distribution
The physical condition of preparing procedure such as constant temperature, speed rate of stirrer and the time duration of emulsifying was important to get the small and uniform particles (Gifani et al. [12] ), therefore when the stirrer speed up from 1000 rpm (Cs3-1) to 2000 rpm (Cs3-2) we could get smaller particles. The laser light scattering studies demonstrated that the stirrer speed up could affect the particles size distribution in such a way that the peak of distribution was moved from 700 nm to 300 nm ( Figure 1 ).SEM observations represented that the particles morphology in both particles were spherical and the surfaces were smooth ( Figure 2 ). 
Drug content and drug efficacy
The drug content in three different initial loadings (Cs 1, Cs 2, Cs 3) was 25%, 35%, 35% (w/w) and the drug efficacies were caculated according to equation (1): 
Drug release
Chitosan has been largely evaluated as a potential polymer for drug administrated orally because of its cationic nature and high charge density in a solution. Chitosan has been reported to enhance absorption of various compounds across the mucosal barrier owing to its properties of mucoadhesion, which increase the contact time of the drug with the mucosa, and its ability to induce a transient opening of epithelial cell tight junctions (Sarmento et al. [1] , Chenguang et al. [13] ). Thus sustained release and improved bioavailability of drugs can be achieved. In vitro drug release for 3 formulations was studied in buffer phosphate solution (pH 7.4). The release profiles of SA were depicted in Figure 3 . The release behaviour of samples in general was the same, but the difference was in the rate of drug release and the amount of burst release. All the nanoparticles prepared had a burst release initially. When the amount of SA increased from Cs 1 to Cs 2, the drug release increased but the release behavior of Cs3 was same as Cs 2 . Becouse the drug content of both of them was equal. Generally when the hydrogen ions concentrations in solution are high the free amine groups within the molecular chains of chitosan form cations (-NH3 + ), therefore, the intermolecular forces (hydrogen bondings) become lower than intramolecular forces (hydrogen bondings) and the buffer solution diffuses readily (Taghizadeh et al. [3] ). Subsequently by increasing the amount of SA, the swelling of nanoparticles should be improved. Due to two different functionl groups (OH,COOH) of SA, two opposite effects on swelling was expected and it can play the role of cross linking agent for chitosan chains as well. According to Table 1 , by addition of SA, the swelling ratio from sample Cs2 to Cs3 was reduced. On the other hand, although it was expected by addition of SA the swelling ratio and amount of drug release should be increased but it was observed that in samples Cs2 and Cs3 the swelling ratio reduced but the drug release was constant. therefore the crosslinking role of SA was more effective in this system. Tab. 1. Drug content, loading efficiacy and swelling ratio of nanoparticles with various amounts of SA. The square root of time or Higuchi model described release by Fickian diffusion (Kiortsis et al. [15] ). The analysis of the release mechanism by mean of the Higuchi equation 2 did not show linear plots and good correlation coefficients in total time of release but release mechanism could fit with this model in time of burst released (Table 2, Figure 4 ). (2) where Q t is the cumulative amount of drug released at time t and K H is the release rate constant (Gifani et al. [12] , Kiortsis et al. [15] 
Higuchi equation: Q t =K H t 1/2
Conclusions
In this manuscript we have successfully prepared chitosan nanoparticles containing maximum 35% (w/w) of SA with emulsion solvent diffusion "in oil" method and evaluated their morphology, drug content and drug release. All the particles had spherical and smooth surface and the peak of their size distribution was in 300 nm. In all nanoparticles there was a burst release which fitted to Higuchi model.
Experimental
Materials
Salicylic acid was purchased from TEMAD Co (I.R. Iran). Petroleum ether and glutaraldehyde were from Aldrich chemical company (USA). Paraffin and Span 80 was obtained from MERCK Co (Germany). Chitosan (M: 780,000 DD: 61.5) were obtained from Fluka Co (Switzerland) and modified as a required DD: 75 (3).
Nanoparticles preparation
Water in oil (W/O) emulsion was prepared by emulsifying the aqueous phase in small and uniform droplets into oil phase (Figure 4 ) (Chenguang et al. [13] ). The aqueous phase contained 0.045gr chitosan and three different amount of SA dissolved into 4.5 ml acetic acid 1% (v/v). The oil phase contained 29.6 ml paraffin and 0.4 cc span80. The mixing rate was modified to 2000 rpm to get the smaller nanoparticles. The temperature was 40 °C during the emulsification. The stable emulsion was crosslinked by 0.08 cc glutaraldehyde 25% (v/v). To separate the particles, it was centrifuged (refrigerated centrifuge 2-16KC, SIGMA, Germany) at high speed and washed twice with petroleum ether and dried in room temperature. 
Nanoparticles morphology and size distribution
SEM photographs were taken using a scanning electron microscope (Tescan Vega ІІ SEM, Czech Republic) at suitable magnification at room temperature. The photographs were observed for morphological and structural characteristics and to confirm the spherical nature of nanoparticles. Particle size distribution of the nanoparticles was determined by laser light scattering with the mean diameter calculated from the cumulative distribution curve (SEMATech, SEM-633, France). Each analysis was performed at 25 ºC with an angle detection of 90º. The refractive index was 1.333 and the wavelength was 632.8 nm.
Drug content
A specific amount of nanoparticles (0.01g) were accurately weighed and transferred to 6 ml of acetic acid 1% (v/v), which can solve the polymer and the drug. The mixture was shaken for 24 hours to make sure all amount of drug solved. The SA concentration in acetic acid was assayed spectrophotometrically (UV-1650 PC; UV Visible Spectrophotometer: Shimadzu). All experiments were performed in triplicate.
Release study
To study the in-vitro drug release, the nanoparticles (0.006 g) were put into dark glasses with a capacity of 20 ml containing 10 ml of phosphate buffer (pH 7.4). The glasses were shaken horizontally and constantly in a temperature controlled shaker (Shaker Incubator 1000, Heidolph, Unimax1010 DT., 37 °C and 100 rpm). Samples (3 ml) were withdrawn at specified time intervals up to 48 h and replaced with fresh medium and assayed by a UV spectrophotometer (296 nm). All experiments were performed in triplicate. Then the cumulative amount of drug released at time t (Q t ) was reported.
Swelling study
The dried nanoparticles were allowed to swell in phosphate buffer (pH 7.4) at the same release condition. At timed intervals, samples were removed from buffer and weighed after excess water on the surfaces was blotted. All experiments were performed in triplicate. The swelling ratios (Q s ) of nanoparticles were calculated from the Equation 3 (Shian Tsai et al. [14] ):
where W d is the weight of the dry nanoparticles while W s is the weight of the swollen nanoparticles at certain time intervals.
